Equities

Akero Therapeutics Inc

Akero Therapeutics Inc

Actions
  • Price (EUR)31.63
  • Today's Change-0.89 / -2.74%
  • Shares traded200.00
  • 1 Year change+125.93%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments550351188
Total Receivables, Net------
Total Inventory------
Prepaid expenses9.953.725.32
Other current assets, total------
Total current assets560355194
Property, plant & equipment, net1.031.291.55
Goodwill, net------
Intangibles, net------
Long term investments19----
Note receivable - long term------
Other long term assets0--0.31
Total assets580357196
LIABILITIES
Accounts payable7.047.976.71
Accrued expenses121118
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities191925
Total long term debt259.540
Total debt259.540
Deferred income tax------
Minority interest------
Other liabilities, total0.871.381.31
Total liabilities453026
SHAREHOLDERS EQUITY
Common stock0.010.010.00
Additional paid-in capital1,109749479
Retained earnings (accumulated deficit)(574)(422)(310)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.270.04(0.03)
Total equity535327169
Total liabilities & shareholders' equity580357196
Total common shares outstanding564735
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.